Global Bovine Respiratory Disease Treatment Market 2022 to 2030: Players Include Bayer, Boehringer Ingelheim, Bimeda, Ceva and Elanco

DUBLIN, Jan. 26, 2023 /PRNewswire/ -- The "Bovine Respiratory Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to  ResearchAndMarkets.com's offering.

This report provides investors, developers, company executives and industry participants with in-depth analysis to allow them to take strategic initiatives and decisions related to the prospects in the global bovine respiratory disease treatment market. This report presents and analyzes the major trends prevalent in the global bovine respiratory disease treatment market and the market size and forecast.

This report categorizes the global bovine respiratory disease treatment market in terms of treatment type, disease type, distribution channel and geographical distribution. Based on treatment types, the global bovine respiratory disease treatment market is categorized into vaccines, antibiotics, immunomodulators and others.

Pneumonia, upper respiratory tract infections and diphtheria are the major disease types considered where bovine respiratory drugs are administered. In terms of distribution channels, this market is categorized into hospitals, clinics, research institutions and others.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global bovine respiratory disease treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study.

Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the industrial rubber goods market. The key players profiled in this report are Bayer AG, Boehringer Ingelheim GmbH, Bimeda, Ceva, Elanco, Merck & Co., Inc., Merial, Virbac Group, Vetoquinol, and Zoetis Services LLC.

Segmentations Analysis

Vaccines form the largest treatment type for bovine respiratory treatment. The demand for bovine respiratory disease drugs is the highest in cattle farms. In such form of animal husbandry, disease prevention have a critical status for ensuring overall cattle health and consequently operational output.

Among the disease types, upper respiratory tract infections have the largest prevalence in cattle. Demand for upper respiratory tract infection drugs is the highest in emerging markets of Latin America and Asia Pacific, due to high prevalence of such infections. Hospitals form the largest distribution channel for bovine respiratory disease drugs.

Local farmers and breeders often enter into long term alliances with veterinary hospitals to meet their period needs for vaccination and regular check-ups of their cattle. Clinics, on the other hand have a considerable yet fast progressing status in the market. Proliferation of drug administration from clinics is observed to be the highest in regions where the veterinary healthcare system is not yet fully established.

Geographically, the global bovine respiratory diseases treatment market is cumulative to North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Among the considered regional markets, North America currently dominates the global bovine respiratory disease treatment market, followed by Europe. Maturity of veterinary healthcare market in North America and Western Europe significantly contribute to the dominance of these regions.

Other factors contributing to the success of North America and Europe markets are existence of well-structured animal husbandry industry, and ready availability of most advanced veterinary healthcare services and drugs. Asia Pacific market is anticipated to progress at the fastest growth rate during the forecast period.

The growth of Asia Pacific market is majorly attributed to rapidly increasing demand for animal protein food and processed meat, substantial proliferation of animal husbandry business and evolution of veterinary healthcare infrastructure in the region. Market players have also intensified their efforts towards increasing their footprints in the untapped emerging markets in order to gain profitability and maintain competitive edge.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

Key Questions Answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Bovine Respiratory Disease Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Bovine Respiratory Disease Treatment market?
• Which is the largest regional market for Bovine Respiratory Disease Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Bovine Respiratory Disease Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Bovine Respiratory Disease Treatment market worldwide?

Key Topics Covered:

 1. Preface

2. Executive Summary

3. Bovine Respiratory Disease Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Bovine Respiratory Disease Treatment Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter's Five Force Model
3.7. PESTEL Analysis

4. Bovine Respiratory Disease Treatment Market: By Treatment, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Vaccines
4.3.2. Antibiotics
4.3.3. Immunomodulators
4.3.4. Others

5. Bovine Respiratory Disease Treatment Market: By Disease, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Pneumonia
5.3.2. Upper Respiratory Tract Infections
5.3.3. Diphtheria

6. Bovine Respiratory Disease Treatment Market: By Distribution Cannel, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Research Institutions
6.3.4. Others

7. North America Bovine Respiratory Disease Treatment Market, 2020-2030, USD (Million)

8. UK and European Union Bovine Respiratory Disease Treatment Market, 2020-2030, USD (Million)

9. Asia Pacific Bovine Respiratory Disease Treatment Market, 2020-2030, USD (Million)

10. Latin America Bovine Respiratory Disease Treatment Market, 2020-2030, USD (Million)

11. Middle East and Africa Bovine Respiratory Disease Treatment Market, 2020-2030, USD (Million)

12. Company Profile
12.1. Bayer AG
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Boehringer Ingelheim GmbH
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Bimeda
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Ceva
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Elanco
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Merck & Co., Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Merial
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Virbac Group
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Vetoquinol
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Zoetis Services LLC
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Other Notable Players
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/61t32h

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

SOURCE Research and Markets